Literature DB >> 16767352

An unusual case of Candida tropicalis and Candida krusei arthritis in a patient with acute myelogenous leukemia before chemotherapy.

Hon-Pin Wang1, Yung-Feng Yen, Wei-Sheng Chen, Yuh-Lan Chou, Chang-Youh Tsai, Hsiao-Ning Chang, Chung-Tei Chou.   

Abstract

A 79-year-old male with acute myelogenous leukemia developed acute right knee arthritis during admission, after the use of broad-spectrum antibiotics before chemotherapy. The initial synovial fluid sample appeared to be mildly inflammatory with a low white cell count. The fungal septic arthritis was not diagnosed until Candida tropicalis, a rare species of Candida, was isolated in the synovial fluid. Although fluconazole is effective in treating the microorganism, the untreated leukemia rendered the infection incurable and led to the growth of fluconazole-resistant Candida krusei. We reported the unusual case of fungal arthritis and reviewed the literature.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16767352     DOI: 10.1007/s10067-006-0336-9

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  9 in total

1.  Candida arthritis treated with amphotericin B.

Authors:  D G Poplack; S A Jacobs
Journal:  J Pediatr       Date:  1975-12       Impact factor: 4.406

2.  Candida tropicalis arthritis of the knee in a patient with acute lymphoblastic leukaemia: successful treatment with caspofungin.

Authors:  J P Y Sim; B C S Kho; H S Y Liu; R Yung; J C W Chan
Journal:  Hong Kong Med J       Date:  2005-04       Impact factor: 2.227

Review 3.  Candida tropicalis arthritis in a patient with acute myeloid leukemia successfully treated with fluconazole: case report and review of the literature.

Authors:  G Weers-Pothoff; J F Havermans; J Kamphuis; H A Sinnige; J F Meis
Journal:  Infection       Date:  1997 Mar-Apr       Impact factor: 3.553

4.  The epidemiology of hematogenous candidiasis caused by different Candida species.

Authors:  D Abi-Said; E Anaissie; O Uzun; I Raad; H Pinzcowski; S Vartivarian
Journal:  Clin Infect Dis       Date:  1997-06       Impact factor: 9.079

5.  Candida tropicalis fungaemia in adult patients with haematological malignancies: clinical features and risk factors.

Authors:  A Y H Leung; C S Chim; P L Ho; V C C Cheng; K Y Yuen; A K W Lie; W Y Au; R Liang; Y L Kwong
Journal:  J Hosp Infect       Date:  2002-04       Impact factor: 3.926

6.  Two unusual strains of Candida arthritis.

Authors:  D R Mandel; A M Segal; A J Wysenbeek; L H Calabrese
Journal:  Am J Med Sci       Date:  1984 Jul-Aug       Impact factor: 2.378

7.  Septic arthritis due to Candida species on patients with cancer: report of five cases and review of the literature.

Authors:  V Fainstein; C Gilmore; R L Hopfer; A Maksymiuk; G P Bodey
Journal:  Rev Infect Dis       Date:  1982 Jan-Feb

Review 8.  Candida arthritis in adult patients who are not intravenous drug addicts: report of three cases and review of the literature.

Authors:  E Cuende; C Barbadillo; R E-Mazzucchelli; C Isasi; A Trujillo; J L Andréu
Journal:  Semin Arthritis Rheum       Date:  1993-02       Impact factor: 5.532

9.  Candida krusei infectious arthritis. A rare complication of neutropenia.

Authors:  V Q Nguyen; R L Penn
Journal:  Am J Med       Date:  1987-11       Impact factor: 4.965

  9 in total
  2 in total

1.  Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei.

Authors:  Erwin Lamping; Amrita Ranchod; Kenjirou Nakamura; Joel D A Tyndall; Kyoko Niimi; Ann R Holmes; Masakazu Niimi; Richard D Cannon
Journal:  Antimicrob Agents Chemother       Date:  2008-11-17       Impact factor: 5.191

2.  Candida Arthritis: Analysis of 112 Pediatric and Adult Cases.

Authors:  Maria N Gamaletsou; Blandine Rammaert; Marimelle A Bueno; Nikolaos V Sipsas; Brad Moriyama; Dimitrios P Kontoyiannis; Emmanuel Roilides; Valerie Zeller; Saad J Taj-Aldeen; Andy O Miller; Ruta Petraitiene; Olivier Lortholary; Thomas J Walsh
Journal:  Open Forum Infect Dis       Date:  2015-12-23       Impact factor: 3.835

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.